This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Allan Fox Biography and Net Worth

Director of REGENXBIO

Allan Fox is the founding partner of FOXKISER, a nationally recognized firm specializing in biomedical research and development, law and public policy. He has created and built numerous ventures in both the public and private sectors. Mr. Fox specializes in identifying business opportunities and improving competitive market position in highly regulated industries, particularly health care.

Before forming FOXKISER, Mr. Fox established the Washington office of the law firm of Kaye, Scholer, Fierman, Hays & Handler. While in the public sector, he served as Chief of Staff and Chief Legislative Assistant to U.S. Senator Jacob K. Javits of New York. He also served as Chief Counsel to the U.S. Senate Health and Scientific Research Subcommittee, chaired by Senator Edward M. Kennedy. Mr. Fox was a Fellow in Law, Science and Medicine at Yale Law School where he received an LL.M. degree. Mr. Fox also holds a J.D. and B.A. from Temple University.

How do I contact Allan M. Fox?: The corporate mailing address for Mr. Fox and other REGENXBIO executives is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. REGENXBIO can also be reached via phone at (240) 552-8181 and via email at [email protected]. Learn More on Allan M. Fox's contact information.
Has Allan M. Fox been buying or selling shares of REGENXBIO?: Allan M. Fox has not been actively trading shares of REGENXBIO during the last quarter. Most recently, Allan M. Fox sold 61,638 shares of the business's stock in a transaction on Wednesday, December 22nd. The shares were sold at an average price of $34.40, for a transaction totalling $2,120,347.20. Learn More on Allan M. Fox's trading history.
Who are REGENXBIO's active insiders?: REGENXBIO's insider roster includes Allan Fox (Director), Kenneth Mills (CEO), Kenneth Mills (CEO), and Steve Pakola (Insider). Learn More on REGENXBIO's active insiders.
Are insiders buying or selling shares of REGENXBIO?: In the last twelve months, insiders at the biotechnology company sold shares 17 times. They sold a total of 255,394 shares worth more than $4,299,705.51. The most recent insider tranaction occured on October, 1st when Director Argeris N Karabelas sold 10,000 shares worth more than $101,100.00. Insiders at REGENXBIO own 13.1% of the company. Learn More about insider trades at REGENXBIO.
Information on this page was last updated on 10/1/2024.

Allan M. Fox Insider Trading History at REGENXBIO

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/22/2021	Sell	61,638	$34.40	$2,120,347.20
9/17/2021	Sell	48,233	$45.04	$2,172,414.32

Allan M. Fox Buying and Selling Activity at REGENXBIO

REGENXBIO Company Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Today's Range

Now: $9.63

$9.01

$9.80

50 Day Range

MA: $10.37

$8.59

$12.95

2 Week Range

Now: $9.63

$8.53

$28.80

Volume

804,939 shs

Average Volume

866,437 shs

Market Capitalization

$477.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23